Pushkal Garg, MD, Chief Medical Officer at Alnylam provides an overview of his company and its focus on RNA interference (RNAi). This new class of innovative medicines has the potential to transform the lives of patients who have limited or inadequate treatment options. RNAi is based on Nobel Prize-winning science and has the potential for treatments of a wide range of debilitating diseases with unmet medical need.